⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
MRK News
Merck & Co., Inc.
BCL-2 Inhibitors Market Poised for Robust Growth During the Forecast Period (2025-2034) as Oncology Pipelines Expand | DelveInsight
prnewswire.com
ABBV
AMGN
AZN
BMY
GILD
JNJ
LLY
MRK
NVS
PFE
SNY
TMO
3 Day Pharma Mini MBA Training Course: Translate Your Learning Into New Behaviours and Improvements (ONLINE EVENT: Mar 18th - Mar 20th, 2026)
globenewswire.com
PFE
MRK
JNJ
GSK
BioNJ Elects Board Officers and Trustees
prnewswire.com
GMAB
MRK
AMTX
JNJ
ASND
ACAD
BMY
PFE
PTC
NVS
SNY
CLDX
Merck Manuals: What Patients and Parents Need to Know About Norovirus
prnewswire.com
MRK
Merck Advances Treatment of Bladder and Kidney Cancers with New Data at 2026 ASCO GU Cancers Symposium
businesswire.com
MRK
EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight
prnewswire.com
AVBP
SMMT
MRUS
MRK
GNPX
CGEM
ABBV
BMY
BDTX
LTRN
PFE
JNJ
LLY
What’s Behind the World’s USD 43.36 Billion Investment in Bioreactors by 2034?
globenewswire.com
TMO
DHR
MRK
KEYTRUDA ® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Plus Paclitaxel ± Bevacizumab, Approved for Certain Adults with PD-L1+ (CPS ≥1) Platinum-Resistant Ovarian Carcinoma as Second or Third Line Treatment
businesswire.com
MRK
Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma (EOC)
businesswire.com
A
MRK
Molecule Found to Drive Skin Cancer Growth and Evade Immune Detection
prnewswire.com
BMY
MRK